No financing, no NASDAQ and note conversions are hurting the company and those conversions increase the float and are dumped into the market ........the pps tells the story. Joe's vision looks good on paper but it appears to fail in the real world for whatever reason ........
Maybe he should step down and hire an experienced big pharma guy to take it to the next level ! People get excited about the clinical trials but they take time, maybe we don't have time and most don't even make it to ph3.
The bright light is the 250M rev estimate /yr, that's only 4.8M / week ..........I forgot the target date but maybe Q3 will clarify the numbers.